← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 3
H2 receptor antagonist (H2 receptor antagonist)
Merck Sharp & Dohme LLC·Lung Neoplasm Malignant
31 trials
Overview
Program
H2 receptor antagonist
Overview
Company
Merck Sharp & Dohme LLC
Overview
Modality
ANTIBODY
Overview
Target
Lung Neoplasm Malignant
Overview
Indication
Ovarian Cancer; Fallopian Tube Cancer
Overview
Phase
PHASE_3
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Biomarker
biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic c
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat
PK/PD
Experiment
pharmacodynamic
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat
Toxicology
Major finding
Small Intestinal Bacterial Overgrowth in a Healthy Female Patient Caused by Long-term Oral Proton Pump Inhibitor Administration.. Small-intestinal bacterial overgrowth (SIBO) causes gastrointestinal symptoms. Proton pump inhibitors (PPIs) are commonly used for acid peptic diseases; however, their long-term use can alter the gut microbiota, resulting in adverse effects. We herein report the case of…
Clinical
Safety signal
Small Intestinal Bacterial Overgrowth in a Healthy Female Patient Caused by Long-term Oral Proton Pump Inhibitor Administration.. Small-intestinal bacterial overgrowth (SIBO) causes gastrointestinal symptoms. Proton pump inhibitors (PPIs) are commonly used for acid peptic diseases; however, their long-term use can alter the gut microbiota, resulting in adverse effects. We herein report the case of…
Clinical
Program phase
PHASE_3
Preclinical
Animal (cat.)
Rat